Cobimetinib 20mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 20mg

Reference Brands: Cotellic (USA/EU)

Category: Oncology Cancer Care

Cobimetinib is a MEK inhibitor used in combination with vemurafenib to treat patients with unresectable or metastatic melanoma that has a BRAF V600E or V600K mutation. It works by blocking the MEK1 and MEK2 enzymes in the MAPK signaling pathway, which helps slow or stop cancer cell growth.

Product Description:

Cobimetinib blocks MEK1 and MEK2, the kinases immediately downstream of BRAF in the MAPK pathway. It exists because BRAF inhibitors used alone fail predictably: within months the pathway reactivates below the point of blockade and the tumour returns. Inhibiting MEK at the same time closes that escape route, which is why cobimetinib is licensed only in combination with vemurafenib rather than as a single agent.

The indication is unresectable or metastatic melanoma carrying a BRAF V600E or V600K mutation, confirmed by a validated test. The combination substantially extends progression-free survival compared with a BRAF inhibitor alone. Characteristic adverse effects include serous retinopathy and other visual disturbances, which require baseline and periodic ophthalmic assessment; reduced left ventricular ejection fraction; photosensitivity severe enough to need strict sun avoidance; diarrhoea; and raised creatine kinase with a risk of rhabdomyolysis.

Sourcing notes. Originator product, under patent in the major markets. Because it is never used alone, demand is tied to vemurafenib supply and both are usually tendered together. A destination market without BRAF mutation testing cannot use it. Oral tablets, room temperature, no special handling beyond cytotoxic precautions in pharmacy.